The rising cost of health care in the United States has been the focus of intense debate within the medical, legal, and legislative arenas, with the cost of cancer care representing an important component. Cost effectiveness is not always easy to define, and there is no standard metric in assessing this measure related to cancer therapies. Significant controversy surrounds exactly what is the appropriate cost per added year of life. This review examines cost, effectiveness, and comparative cost effectiveness of novel systemic therapies for patients with urologic malignancies. Cancer 2018;124:2897-905. © 2018 American Cancer Society.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.31355 | DOI Listing |
Publication Analysis
Top Keywords
cost effectiveness
12
cost
7
cost considerations
4
considerations systemic
4
systemic therapy
4
therapy patients
4
patients advanced
4
advanced genitourinary
4
genitourinary malignancies
4
malignancies rising
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!